{"shortAnswer":"Semaglutide is FDA-approved as Ozempic, Wegovy and Rybelsus, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk. Copies made by pharmacies or sold for research use are not approved, and FDA has not checked them.","url":"https://peptideindex.ai/compound/semaglutide","status":"fda-approved","statusCheckedAt":"2026-10-24T05:02:14.779Z","statusStale":false,"regulatoryAsOf":"2026-10-23","verified":"2026-10-25T17:34:40.564Z","primarySourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"b3fe59a6-4944-4500-b3c0-f5d978cb544e","object":"compound","slug":"semaglutide","name":"Semaglutide","attrs":{"name":"Semaglutide","class":"glp-1-agonist","access":[{"type":"approved-product","detail":"Approved by FDA and sold with a prescription as weekly shots and daily pills. Ozempic and Rybelsus are for type 2 diabetes. Wegovy is for weight loss and heart risk.","indication":"Type 2 diabetes, and lower heart and kidney risk in some adults with it (Ozempic, Rybelsus). Weight loss, lower heart risk, and a fatty liver disease called MASH (Wegovy).","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","brand_names":["Ozempic","Wegovy","Rybelsus"],"manufacturer":"Novo Nordisk"},{"type":"lawful-compounding","detail":"FDA said the shortage ended on 21 February 2025. A pharmacy may make a version for one patient only when the prescriber writes down why that patient needs a change from the approved drug. Regular copies of the approved drug are not allowed.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"}],"dosing":"From the Wegovy label. Wegovy shot: once a week, starting at 0.25 mg for 4 weeks and going up every 4 weeks. The usual dose to stay on is 2.4 mg a week, and some adults may go up to 7.2 mg. Wegovy pill: once a day on an empty stomach, starting at 1.5 mg for 30 days and going up every 30 days to 25 mg. Ozempic and Rybelsus have their own schedules on their labels. The prescriber sets the dose.","trials":[{"nct":"NCT07586150","url":"https://clinicaltrials.gov/study/NCT07586150","phase":"Not applicable","title":"Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)","status":"not-yet-recruiting","sponsor":"Ludwig-Maximilians - University of Munich","countries":["Austria","Germany","Netherlands"],"us_states":[]},{"nct":"NCT07430332","url":"https://clinicaltrials.gov/study/NCT07430332","phase":"Phase 2","title":"GLP-1 RA for Stage 1 Type 1 Diabetes","status":"not-yet-recruiting","sponsor":"Children's Hospital Medical Center, Cincinnati","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT07797036","url":"https://clinicaltrials.gov/study/NCT07797036","phase":"Phase 2/Phase 3","title":"Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus","status":"not-yet-recruiting","sponsor":"University of Massachusetts, Worcester","countries":["United States"],"us_states":["Massachusetts"]},{"nct":"NCT07711548","url":"https://clinicaltrials.gov/study/NCT07711548","phase":"Not applicable","title":"Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?","status":"not-yet-recruiting","sponsor":"Knut Mai","countries":[],"us_states":[]},{"nct":"NCT07754045","url":"https://clinicaltrials.gov/study/NCT07754045","phase":"Phase 2","title":"Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults","status":"not-yet-recruiting","sponsor":"Lumos Pharma","countries":[],"us_states":[]},{"nct":"NCT07731256","url":"https://clinicaltrials.gov/study/NCT07731256","phase":"Phase 2","title":"Semaglutide for Low Back Pain","status":"not-yet-recruiting","sponsor":"Washington University School of Medicine","countries":["United States"],"us_states":["Alabama","Missouri"]},{"nct":"NCT05714683","url":"https://clinicaltrials.gov/study/NCT05714683","phase":"Not stated","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"not-yet-recruiting","sponsor":"Novo Nordisk A/S","countries":[],"us_states":[]},{"nct":"NCT07879612","url":"https://clinicaltrials.gov/study/NCT07879612","phase":"Phase 2","title":"Semaglutide for the Treatment of Cannabis Use Disorder","status":"not-yet-recruiting","sponsor":"Massachusetts General Hospital","countries":[],"us_states":[]},{"nct":"NCT07462663","url":"https://clinicaltrials.gov/study/NCT07462663","phase":"Phase 4","title":"SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer","status":"not-yet-recruiting","sponsor":"Hospital Universitari de Bellvitge","countries":[],"us_states":[]},{"nct":"NCT07614412","url":"https://clinicaltrials.gov/study/NCT07614412","phase":"Phase 2","title":"SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.","status":"not-yet-recruiting","sponsor":"Ministry of Health, Saudi Arabia","countries":["Saudi Arabia"],"us_states":[]},{"nct":"NCT07820358","url":"https://clinicaltrials.gov/study/NCT07820358","phase":"Phase 2","title":"Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer","status":"not-yet-recruiting","sponsor":"The Methodist Hospital Research Institute","countries":["United States"],"us_states":["Texas"]},{"nct":"NCT07787936","url":"https://clinicaltrials.gov/study/NCT07787936","phase":"Not stated","title":"GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry","status":"not-yet-recruiting","sponsor":"Miedziowe Centrum Zdrowia SA","countries":["Poland"],"us_states":[]},{"nct":"NCT07858331","url":"https://clinicaltrials.gov/study/NCT07858331","phase":"Phase 4","title":"Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access","status":"not-yet-recruiting","sponsor":"Kristin Clemens","countries":["Canada"],"us_states":[]},{"nct":"NCT07760948","url":"https://clinicaltrials.gov/study/NCT07760948","phase":"Phase 2","title":"HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide","status":"not-yet-recruiting","sponsor":"Vanderbilt University Medical Center","countries":["United States"],"us_states":["Tennessee"]},{"nct":"NCT07770282","url":"https://clinicaltrials.gov/study/NCT07770282","phase":"Phase 3","title":"Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome","status":"not-yet-recruiting","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","countries":[],"us_states":[]},{"nct":"NCT06977438","url":"https://clinicaltrials.gov/study/NCT06977438","phase":"Phase 4","title":"GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward","status":"not-yet-recruiting","sponsor":"University of Minnesota","countries":["United States"],"us_states":["Minnesota"]},{"nct":"NCT07855900","url":"https://clinicaltrials.gov/study/NCT07855900","phase":"Phase 3","title":"SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight","status":"not-yet-recruiting","sponsor":"Boehringer Ingelheim","countries":["United States"],"us_states":["Florida"]},{"nct":"NCT07866066","url":"https://clinicaltrials.gov/study/NCT07866066","phase":"Phase 3","title":"Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes","status":"not-yet-recruiting","sponsor":"Amgen","countries":[],"us_states":[]},{"nct":"NCT07249554","url":"https://clinicaltrials.gov/study/NCT07249554","phase":"Phase 2","title":"Combination Therapy for Alcohol Use Disorder","status":"not-yet-recruiting","sponsor":"Johns Hopkins University","countries":["United States"],"us_states":["Maryland"]},{"nct":"NCT07878494","url":"https://clinicaltrials.gov/study/NCT07878494","phase":"Not applicable","title":"Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia","status":"not-yet-recruiting","sponsor":"Stanford University","countries":["United States"],"us_states":["California"]},{"nct":"NCT06546384","url":"https://clinicaltrials.gov/study/NCT06546384","phase":"Not applicable","title":"GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","status":"not-yet-recruiting","sponsor":"Insel Gruppe AG, University Hospital Bern","countries":["Switzerland"],"us_states":[]},{"nct":"NCT07832084","url":"https://clinicaltrials.gov/study/NCT07832084","phase":"Phase 4","title":"Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s","status":"not-yet-recruiting","sponsor":"Jing Luo","countries":["United States"],"us_states":["Pennsylvania"]},{"nct":"NCT07027969","url":"https://clinicaltrials.gov/study/NCT07027969","phase":"Phase 4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"not-yet-recruiting","sponsor":"Ali Aminian","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT07845994","url":"https://clinicaltrials.gov/study/NCT07845994","phase":"Phase 3","title":"SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years","status":"not-yet-recruiting","sponsor":"University Hospital, Angers","countries":["France"],"us_states":[]},{"nct":"NCT07511543","url":"https://clinicaltrials.gov/study/NCT07511543","phase":"Phase 2","title":"Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy","status":"not-yet-recruiting","sponsor":"Population Health Research Institute","countries":[],"us_states":[]},{"nct":"NCT07881783","url":"https://clinicaltrials.gov/study/NCT07881783","phase":"Not stated","title":"A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy","status":"not-yet-recruiting","sponsor":"Novartis Pharmaceuticals","countries":[],"us_states":[]},{"nct":"NCT07840729","url":"https://clinicaltrials.gov/study/NCT07840729","phase":"Phase 1","title":"Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants","status":"not-yet-recruiting","sponsor":"Shanghai JMT-Bio Inc.","countries":["China"],"us_states":[]},{"nct":"NCT07874971","url":"https://clinicaltrials.gov/study/NCT07874971","phase":"Not applicable","title":"Short Term Effects of Semaglutide on Body Composition and Performance","status":"not-yet-recruiting","sponsor":"Morten Hostrup, PhD","countries":["Denmark"],"us_states":[]},{"nct":"NCT07874932","url":"https://clinicaltrials.gov/study/NCT07874932","phase":"Not applicable","title":"Long-Term Effects of Semaglutide on Body Composition and Performance in Running","status":"not-yet-recruiting","sponsor":"Morten Hostrup, PhD","countries":["Denmark"],"us_states":[]},{"nct":"NCT07891156","url":"https://clinicaltrials.gov/study/NCT07891156","phase":"Phase 2/Phase 3","title":"Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.","status":"recruiting","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","countries":["Canada"],"us_states":[]},{"nct":"NCT07881770","url":"https://clinicaltrials.gov/study/NCT07881770","phase":"Not stated","title":"Semaglutide Health Outcomes and Patient Adherence in Australia","status":"not-yet-recruiting","sponsor":"Novo Nordisk A/S","countries":["Australia"],"us_states":[]},{"nct":"NCT07812597","url":"https://clinicaltrials.gov/study/NCT07812597","phase":"Phase 2","title":"A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)","status":"not-yet-recruiting","sponsor":"Beijing QL Biopharmaceutical Co.,Ltd","countries":["China"],"us_states":[]},{"nct":"NCT07627191","url":"https://clinicaltrials.gov/study/NCT07627191","phase":"Early phase 1","title":"GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer","status":"recruiting","sponsor":"University of Arizona","countries":["United States"],"us_states":["Arizona"]},{"nct":"NCT07855133","url":"https://clinicaltrials.gov/study/NCT07855133","phase":"Phase 1","title":"A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication","status":"recruiting","sponsor":"Novo Nordisk A/S","countries":["United States"],"us_states":["California","Maryland"]},{"nct":"NCT07816744","url":"https://clinicaltrials.gov/study/NCT07816744","phase":"Not applicable","title":"Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression","status":"not-yet-recruiting","sponsor":"Axel Brandes","countries":["Denmark"],"us_states":[]},{"nct":"NCT07859137","url":"https://clinicaltrials.gov/study/NCT07859137","phase":"Phase 4","title":"Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher","status":"not-yet-recruiting","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","countries":["Egypt"],"us_states":[]},{"nct":"NCT07423481","url":"https://clinicaltrials.gov/study/NCT07423481","phase":"Not stated","title":"Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity","status":"not-yet-recruiting","sponsor":"Nantes University Hospital","countries":["France"],"us_states":[]},{"nct":"NCT07859150","url":"https://clinicaltrials.gov/study/NCT07859150","phase":"Phase 4","title":"Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)","status":"not-yet-recruiting","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","countries":["Egypt"],"us_states":[]},{"nct":"NCT07872904","url":"https://clinicaltrials.gov/study/NCT07872904","phase":"Phase 4","title":"FutureShape Family","status":"not-yet-recruiting","sponsor":"Signe Torekov","countries":["Denmark"],"us_states":[]},{"nct":"NCT07859189","url":"https://clinicaltrials.gov/study/NCT07859189","phase":"Phase 4","title":"Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery","status":"not-yet-recruiting","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","countries":["Egypt"],"us_states":[]},{"nct":"NCT07389941","url":"https://clinicaltrials.gov/study/NCT07389941","phase":"Phase 4","title":"Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","status":"not-yet-recruiting","sponsor":"University of Luebeck","countries":[],"us_states":[]},{"nct":"NCT07737522","url":"https://clinicaltrials.gov/study/NCT07737522","phase":"Phase 2","title":"Myocardial Metabolic Flux in Pulmonary Arterial Hypertension","status":"not-yet-recruiting","sponsor":"Imperial College London","countries":[],"us_states":[]},{"nct":"NCT07859176","url":"https://clinicaltrials.gov/study/NCT07859176","phase":"Phase 4","title":"Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery","status":"not-yet-recruiting","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","countries":["Egypt"],"us_states":[]},{"nct":"NCT07755085","url":"https://clinicaltrials.gov/study/NCT07755085","phase":"Phase 4","title":"GLP-1s in Hip and Knee Arthroplasty","status":"not-yet-recruiting","sponsor":"Nova Scotia Health Authority","countries":["Canada"],"us_states":[]},{"nct":"NCT07820722","url":"https://clinicaltrials.gov/study/NCT07820722","phase":"Early phase 1","title":"Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI","status":"not-yet-recruiting","sponsor":"Sunnybrook Health Sciences Centre","countries":[],"us_states":[]},{"nct":"NCT07772960","url":"https://clinicaltrials.gov/study/NCT07772960","phase":"Phase 1","title":"Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes","status":"not-yet-recruiting","sponsor":"Yale University","countries":["United States"],"us_states":["Connecticut"]},{"nct":"NCT07859163","url":"https://clinicaltrials.gov/study/NCT07859163","phase":"Phase 4","title":"Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain","status":"not-yet-recruiting","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","countries":["Egypt"],"us_states":[]},{"nct":"NCT07845500","url":"https://clinicaltrials.gov/study/NCT07845500","phase":"Phase 3","title":"A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity","status":"recruiting","sponsor":"Pfizer","countries":["United States"],"us_states":["Alabama","California","Florida","Kentucky","Michigan","Mississippi","Missouri","Montana","North Carolina","Ohio","South Carolina"]},{"nct":"NCT07845578","url":"https://clinicaltrials.gov/study/NCT07845578","phase":"Phase 1","title":"A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight","status":"not-yet-recruiting","sponsor":"Novo Nordisk A/S","countries":["Austria"],"us_states":[]},{"nct":"NCT07668414","url":"https://clinicaltrials.gov/study/NCT07668414","phase":"Phase 3","title":"A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide","status":"recruiting","sponsor":"Novo Nordisk A/S","countries":["United States"],"us_states":["California","District of Columbia","Florida","Georgia","Illinois","Indiana","Louisiana","Missouri","New York","North Carolina","North Dakota","Pennsylvania","South Carolina","Texas","Virginia","Washington"]}],"aliases":["Ozempic","Wegovy","Rybelsus"],"summary":"A prescription drug that copies the gut hormone GLP-1. FDA approved it as Ozempic, Wegovy and Rybelsus for diabetes, weight loss and heart risk.","citations":[{"n":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","tier":"primary","type":"regulatory","title":"Drugs@FDA: Ozempic injection, application 209637"},{"n":2,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","tier":"primary","type":"regulatory","title":"Drugs@FDA: Wegovy injection, application 215256"},{"n":3,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051","tier":"primary","type":"regulatory","title":"Drugs@FDA: Rybelsus and Ozempic tablets, application 213051"},{"n":4,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","tier":"primary","type":"label","title":"DailyMed: Ozempic injection prescribing information, revised May 2026"},{"n":5,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","tier":"primary","type":"label","title":"DailyMed: Wegovy injection and tablets prescribing information, revised June 2026"},{"n":6,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","tier":"primary","type":"label","title":"DailyMed: Rybelsus and Ozempic tablets prescribing information, revised January 2026"},{"n":7,"url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r","tier":"primary","type":"regulatory","title":"FDA drug shortages: semaglutide injection, resolved"},{"n":8,"url":"https://www.fda.gov/media/185526/download","tier":"primary","type":"regulatory","title":"FDA order: the semaglutide injection shortage is resolved, 21 February 2025"},{"n":9,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize","tier":"primary","type":"regulatory","title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026"},{"n":10,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","tier":"primary","type":"regulatory","title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026"},{"n":11,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain","tier":"primary","type":"regulatory","title":"FDA: warnings on counterfeit Ozempic in the US drug supply, 2023 to 2025"},{"n":12,"url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded","tier":"primary","type":"regulatory","title":"FDA: dosing errors with compounded semaglutide injections, 2024"},{"n":13,"url":"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs","tier":"primary","type":"regulatory","title":"FDA statement: action against non-approved GLP-1 drugs, 6 February 2026"},{"n":14,"url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list","tier":"primary","type":"regulatory","title":"FDA: proposal to exclude semaglutide from the 503B bulks list, 30 April 2026"},{"n":15,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026","tier":"primary","type":"regulatory","title":"FDA warning letter to an online seller of research-use peptides, 24 August 2026"},{"n":16,"url":"https://www.mcdermottlaw.com/insights/semaglutide-shortage-resolved/","tier":"legal-analysis","type":"legal-analysis","title":"McDermott Will & Schulte: what the end of the semaglutide shortage means"},{"n":17,"url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs","tier":"legal-analysis","type":"legal-analysis","title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/27633186/","tier":"peer-reviewed","type":"rct","title":"SUSTAIN-6: semaglutide and heart outcomes in type 2 diabetes, 2016"},{"n":19,"url":"https://pubmed.ncbi.nlm.nih.gov/33567185/","tier":"peer-reviewed","type":"rct","title":"STEP 1: weekly semaglutide in adults with overweight or obesity, 2021"},{"n":20,"url":"https://pubmed.ncbi.nlm.nih.gov/37952131/","tier":"peer-reviewed","type":"rct","title":"SELECT: semaglutide and heart outcomes in obesity without diabetes, 2023"},{"n":21,"url":"https://pubmed.ncbi.nlm.nih.gov/39396098/","tier":"peer-reviewed","type":"systematic-review","title":"Review of heart outcomes and harms of semaglutide in overweight or obesity, 2024"},{"n":22,"url":"https://pubmed.ncbi.nlm.nih.gov/40810985/","tier":"peer-reviewed","type":"systematic-review","title":"Review of eye disorders, including an optic nerve problem, with semaglutide, 2025"},{"n":23,"url":"https://www.statnews.com/pharmalot/2026/04/30/fda-weight-loss-drugs-new-rule-would-end-glp-1-compound-pharmacy/","tier":"established-news","type":"reference","title":"STAT: FDA proposes a rule that would end bulk compounding of GLP-1 drugs"},{"n":24,"url":"https://www.nbcnews.com/health/health-news/fda-proposes-compounded-ozempic-zepbound-wegovy-weight-loss-telehealth-rcna342957","tier":"established-news","type":"reference","title":"NBC News: FDA proposes keeping weight-loss drugs off a key compounding list"}],"known_risks":["In rats and mice, semaglutide caused thyroid tumors. The labels warn people with a rare thyroid cancer in the family not to use it [^4] [^5].","The most common problems are nausea, vomiting, diarrhea, belly pain and constipation [^4]. More people on it than on a dummy shot quit for stomach trouble [^19].","The labels warn of a swollen pancreas and gallbladder disease. They also warn of kidney harm from losing fluids, and of bad allergic reactions [^4] [^5].","Taken with insulin or some other diabetes drugs, it can push blood sugar too low [^4].","In a diabetes trial, eye damage from diabetes got worse more often in people on semaglutide [^18].","FDA has reports of people who took 5 to 20 times the intended amount of compounded semaglutide. Some went to the hospital [^12]."],"short_answer":"Semaglutide is FDA-approved as Ozempic, Wegovy and Rybelsus, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk. Copies made by pharmacies or sold for research use are not approved, and FDA has not checked them.","evidence_grade":"strong-human","open_questions":["Nobody knows if it can cause thyroid cancer in people. The rat and mouse studies do not tell us [^4].","A 2025 review linked it to a rare eye nerve problem that can take away sight. The evidence is too thin to say it is the cause [^22].","The main weight trial lasted 68 weeks, so it does not show what years of use do [^19].","Nobody knows if the salt forms some pharmacies use act like the approved drug [^10]."],"section_routes":"The legal way to get semaglutide is a prescription for one of the approved brands, filled at a state-licensed pharmacy [^1] [^10]. Ozempic, Wegovy and Rybelsus are each approved by FDA [^1] [^2] [^3]. Each label says who it is for and how it is taken [^4] [^5] [^6].\n\nA copy made by a pharmacy is lawful only in narrow cases. The prescriber has to write down why one patient needs a change from the approved drug, such as an allergy to one of its parts [^16] [^17]. A lower price or a wish for a different form is not enough [^17]. FDA says pharmacy copies should be used only when an approved drug cannot meet a patient's needs [^10]. FDA does not check pharmacy copies for safety, quality or whether they work [^10].\n\nOpen trials are listed in the trials block below, with the date the official registry was last checked.","regulatory_as_of":"2026-10-23","section_channels":"Semaglutide reaches people outside the approved brands in four main ways [^10]. The first is pharmacies that kept making copies after the shortage ended [^9] [^13]. FDA has received reports of harm tied to pharmacy copies and says many more likely go unreported [^10]. The second is online prescribers that sell these copies. FDA has told companies they may not call a copy generic or the same as the approved drug [^13]. The third is fake Ozempic pens. FDA has seized fake pens from the US drug supply three times since 2023 [^11]. The fourth is online sellers that label it for research use. FDA has warned such a seller that the label does not make the sale legal [^15].\n\nIn each case, FDA cannot vouch for what is in the product [^10]. Some pharmacy copies use salt forms, which are a different ingredient from the approved drug [^10] [^12]. Some carry the name of a pharmacy that does not exist or did not make them [^10]. People have taken many times the intended amount by mistake [^12].","section_evidence":"The evidence grade is strong-human: several large trials in people agree that it lowers blood sugar, weight and heart risk [^18] [^19] [^20]. In a two-year trial of 3,297 adults with type 2 diabetes, fewer people on it had a heart attack, a stroke or a heart death than people on a dummy shot [^18]. In a 68-week trial of 1,961 adults with obesity and no diabetes, people on it lost about 15% of their weight. People on the dummy shot lost about 2% [^19]. In a trial of 17,604 adults with heart disease and excess weight but no diabetes, it cut heart attacks, strokes and heart deaths by about a fifth [^20]. A 2024 review of 38 studies found fewer hospital stays for heart failure and fewer deaths. It also found more stomach trouble [^21].\n\nThese trials tested the approved drug from its maker, and the maker paid for them [^18] [^19] [^20]. They tell us nothing about copies made by pharmacies or sold for research use. FDA has not checked those copies for quality [^10].","regulatory_status":"fda-approved","section_what_it_is":"Semaglutide is a prescription drug. It copies GLP-1, a hormone the gut makes after you eat [^4]. GLP-1 helps control blood sugar and makes you feel full. FDA first approved it in 2017 [^4]. One company makes it and sells it under three brand names [^1] [^2] [^3].\n\nOzempic is a weekly shot for type 2 diabetes. It now also comes as a daily pill [^3] [^4]. Wegovy is a weekly shot or a daily pill for weight loss and heart health [^5]. Rybelsus is a daily pill for type 2 diabetes [^6]. The body clears half of a dose in about a week [^4]. That is why the shots are taken once a week.\n\nSome pharmacies and online sellers offer their own copies of it. Those copies are not the approved drug [^10].","section_is_it_legal":"Semaglutide is FDA-approved: FDA first approved it in 2017, and it is sold as Ozempic, Wegovy and Rybelsus [^1] [^2] [^3] [^4]. That covers the brand drugs, with a prescription, for the uses on their labels. It does not make copies from pharmacies or online sellers approved [^10]. Checked 23 October 2026.\n\nOzempic is approved for type 2 diabetes, not for weight loss. Wegovy is the brand approved for weight loss [^4] [^5]. Many copies are sold for weight loss [^12].\n\nThe shots were on FDA's drug shortage list until 2025 [^7] [^8]. During a shortage, pharmacies may make copies of a drug. FDA said the shortage was over on 21 February 2025 [^7] [^8]. Pharmacies had until 22 April 2025 to stop making copies. Larger outsourcing facilities had until 22 May 2025 [^9] [^16]. A court refused to block this in April 2025 [^9].\n\nToday a pharmacy may not make copies of the approved drug as a regular practice [^9]. It may make a different version for one patient. The prescriber has to write down why that patient needs the change [^16] [^17]. FDA says it will not act on four or fewer copy prescriptions a month [^9]. In April 2026, FDA proposed a rule to keep outsourcing facilities from making it from raw powder. The rule is not final [^14] [^17]. Selling it with a research-use label is illegal [^15].","unofficial_channels":[{"type":"compounding-outside-the-rules","what_it_is":"Copies of the approved shots made by pharmacies and outsourcing facilities, often sent in vials that hold several doses.","enforcement":[{"date":"2026-02-06","text":"FDA said it would restrict the raw ingredient used for mass-marketed copies, and warned that seizure and court orders may follow.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs"},{"date":"2026-04-30","text":"FDA proposed keeping semaglutide off the list of bulk ingredients outsourcing facilities may use. The proposal is not final.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"}],"legal_position":{"text":"Since the shortage ended in 2025, a pharmacy may not make copies of the approved drug as a regular practice. FDA knows of no lawful basis for making it from salt forms such as semaglutide sodium.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},"documented_risks":[{"text":"FDA has reports of people who took 5 to 20 times the intended amount from multi-dose vials. Some went to the hospital with vomiting, fainting, a swollen pancreas or gallstones.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"},{"text":"FDA has received reports of harm tied to compounded semaglutide and says many more likely go unreported.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"FDA has found fake compounded semaglutide with labels naming pharmacies that do not exist or did not make it.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}]},{"type":"telehealth","what_it_is":"Online prescribers that sell compounded semaglutide after a short online visit, often by monthly plan.","enforcement":[{"date":"2026-02-06","text":"FDA said it would act against misleading marketing of compounded GLP-1 drugs, after warning letters sent in the fall of 2025.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs"}],"legal_position":{"text":"FDA says a company may not claim a compounded copy is a generic, is the same as the approved drug, or is proven to work.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs"},"documented_risks":[{"text":"FDA reviewed a case where a patient could not get clear instructions from an online prescriber and took five times the intended amount.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"},{"text":"FDA has complaints that compounded GLP-1 drugs arrived warm, which can harm their quality.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}]},{"type":"counterfeit-or-diverted","what_it_is":"Fake Ozempic pens sold outside the maker's own supply chain. Some reached the regular US drug supply.","enforcement":[{"date":"2023-12-21","text":"FDA said it had seized thousands of fake Ozempic pens from the US drug supply.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain"},{"date":"2025-04-14","text":"FDA said it had seized several hundred fake Ozempic pens on 9 April 2025.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain"},{"date":"2025-12-05","text":"FDA said it had found more fake Ozempic pens in the US drug supply.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain"}],"legal_position":{"text":"Counterfeit drugs are illegal, FDA says.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},"documented_risks":[{"text":"A fake drug may hold the wrong ingredient, too much or too little drug, or none at all, FDA warns.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"In fake pens seized in 2023, the needles were also fake, so nobody could confirm they were germ-free.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain"}]},{"type":"research-use-seller","what_it_is":"Sold online as a powder with a label saying it is for research use or not for people.","enforcement":[{"date":"2026-08-24","text":"FDA warning letter to an online seller of research-use peptides, including semaglutide.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"}],"legal_position":{"text":"FDA treats these as unapproved new drugs when the seller's site shows they are meant for people, whatever the label says.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"},"documented_risks":[{"text":"FDA says these products are of unknown quality and may harm health.","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"text":"FDA warns that injected products skip some of the body's defenses, so toxins or germs in them can cause life-threatening illness.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"}]}]},"provenance":{"name":{"fact_id":"85b3a67e-4a88-4672-bc67-812666c61728","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","source_type":"primary","captured_at":"2026-10-24T04:24:22.293Z","checked_at":"2026-10-24T05:02:14.772Z","confidence":1,"stale":false},"class":{"fact_id":"e16b7a98-fe14-48a9-89b4-33bd3480686e","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","source_type":"primary","captured_at":"2026-10-24T04:24:22.293Z","checked_at":"2026-10-24T05:02:14.764Z","confidence":1,"stale":false},"access":{"fact_id":"92407932-202d-4d3b-946a-90d03d69cfc4","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","source_type":"primary","captured_at":"2026-10-24T04:24:22.916Z","checked_at":"2026-10-24T05:02:14.751Z","confidence":1,"stale":false},"dosing":{"fact_id":"76f6c306-e4cd-469d-8645-137ea991848a","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","source_type":"primary","captured_at":"2026-10-24T04:24:22.490Z","checked_at":"2026-10-24T05:02:14.766Z","confidence":1,"stale":false},"trials":{"fact_id":"ccf7e0f7-843c-45ed-8345-ead391711f84","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide+OR+Ozempic+OR+Wegovy+OR+Rybelsus&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-25T00:07:26.723Z","checked_at":"2026-10-25T00:07:26.723Z","confidence":1,"stale":false},"aliases":{"fact_id":"109a8b0a-21eb-4ece-b796-78ebd2707853","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded","source_type":"primary","captured_at":"2026-10-24T04:24:23.575Z","checked_at":"2026-10-24T05:02:14.760Z","confidence":1,"stale":false},"summary":{"fact_id":"f63ef2dd-a6e2-4278-9416-7574f313dc35","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","source_type":"primary","captured_at":"2026-10-24T04:24:22.951Z","checked_at":"2026-10-24T05:02:14.794Z","confidence":1,"stale":false},"citations":{"fact_id":"f7039057-f666-4696-be2a-bffc8835ca88","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","source_type":"primary","captured_at":"2026-10-24T04:24:22.293Z","checked_at":"2026-10-24T05:02:14.762Z","confidence":1,"stale":false},"known_risks":{"fact_id":"786d2539-5f2b-4131-8a8f-e83f97e01265","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","source_type":"primary","captured_at":"2026-10-24T04:24:22.293Z","checked_at":"2026-10-24T05:02:14.770Z","confidence":1,"stale":false},"short_answer":{"fact_id":"c55cc180-898c-4b88-89d6-f3716cbdb4b0","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-24T03:55:12.975Z","checked_at":"2026-10-24T05:02:14.793Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"1beb0240-8faa-4ac4-9e9d-44455efed300","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-24T03:55:13.723Z","checked_at":"2026-10-24T05:02:14.768Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"170520b1-47d8-4d71-8102-65b3385daa00","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","source_type":"primary","captured_at":"2026-10-24T04:24:22.293Z","checked_at":"2026-10-24T05:02:14.774Z","confidence":1,"stale":false},"section_routes":{"fact_id":"4d5467f0-6686-4dd0-933d-50b6d5412c9f","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","source_type":"primary","captured_at":"2026-10-24T04:24:22.916Z","checked_at":"2026-10-25T17:34:40.564Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"f5c4226f-afc9-47da-9758-59e4074620da","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","source_type":"primary","captured_at":"2026-10-24T04:24:22.916Z","checked_at":"2026-10-24T05:02:14.776Z","confidence":1,"stale":false},"section_channels":{"fact_id":"b885325a-33bc-41aa-92a9-6035045b6be0","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:02:14.782Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"271858ef-707f-4318-8d10-1af4570e9f63","source_url":"https://pubmed.ncbi.nlm.nih.gov/33567185/","source_type":"peer-reviewed","captured_at":"2026-10-24T04:25:19.755Z","checked_at":"2026-10-24T05:02:14.784Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"4face4c8-48c0-454d-ac09-1286eef1a395","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","source_type":"primary","captured_at":"2026-10-24T04:24:22.951Z","checked_at":"2026-10-24T05:02:14.779Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"75902826-273b-48d8-b765-a494cf12083e","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","source_type":"primary","captured_at":"2026-10-24T04:24:22.293Z","checked_at":"2026-10-24T05:02:14.791Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"6e37a9a8-6c83-49c9-b8df-01de15e060f5","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","source_type":"primary","captured_at":"2026-10-24T04:24:22.916Z","checked_at":"2026-10-24T05:02:14.786Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"5ce857f0-f8d0-4c3b-bb43-abc02346aa39","source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","source_type":"primary","captured_at":"2026-10-24T04:24:23.450Z","checked_at":"2026-10-24T05:02:14.799Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":4,"title":"DailyMed: Ozempic injection prescribing information, revised May 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79"},{"n":5,"title":"DailyMed: Wegovy injection and tablets prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"n":19,"title":"STEP 1: weekly semaglutide in adults with overweight or obesity, 2021","url":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"n":18,"title":"SUSTAIN-6: semaglutide and heart outcomes in type 2 diabetes, 2016","url":"https://pubmed.ncbi.nlm.nih.gov/27633186/"},{"n":12,"title":"FDA: dosing errors with compounded semaglutide injections, 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"}],"open_questions":[{"n":4,"title":"DailyMed: Ozempic injection prescribing information, revised May 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79"},{"n":22,"title":"Review of eye disorders, including an optic nerve problem, with semaglutide, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/40810985/"},{"n":19,"title":"STEP 1: weekly semaglutide in adults with overweight or obesity, 2021","url":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"n":10,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_routes":[{"n":1,"title":"Drugs@FDA: Ozempic injection, application 209637","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637"},{"n":10,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":2,"title":"Drugs@FDA: Wegovy injection, application 215256","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256"},{"n":3,"title":"Drugs@FDA: Rybelsus and Ozempic tablets, application 213051","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051"},{"n":4,"title":"DailyMed: Ozempic injection prescribing information, revised May 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79"},{"n":5,"title":"DailyMed: Wegovy injection and tablets prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"n":6,"title":"DailyMed: Rybelsus and Ozempic tablets prescribing information, revised January 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98"},{"n":16,"title":"McDermott Will & Schulte: what the end of the semaglutide shortage means","url":"https://www.mcdermottlaw.com/insights/semaglutide-shortage-resolved/"},{"n":17,"title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs","url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs"}],"section_channels":[{"n":10,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":9,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":13,"title":"FDA statement: action against non-approved GLP-1 drugs, 6 February 2026","url":"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs"},{"n":11,"title":"FDA: warnings on counterfeit Ozempic in the US drug supply, 2023 to 2025","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain"},{"n":15,"title":"FDA warning letter to an online seller of research-use peptides, 24 August 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"},{"n":12,"title":"FDA: dosing errors with compounded semaglutide injections, 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"}],"section_evidence":[{"n":18,"title":"SUSTAIN-6: semaglutide and heart outcomes in type 2 diabetes, 2016","url":"https://pubmed.ncbi.nlm.nih.gov/27633186/"},{"n":19,"title":"STEP 1: weekly semaglutide in adults with overweight or obesity, 2021","url":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"n":20,"title":"SELECT: semaglutide and heart outcomes in obesity without diabetes, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37952131/"},{"n":21,"title":"Review of heart outcomes and harms of semaglutide in overweight or obesity, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/39396098/"},{"n":10,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_what_it_is":[{"n":4,"title":"DailyMed: Ozempic injection prescribing information, revised May 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79"},{"n":1,"title":"Drugs@FDA: Ozempic injection, application 209637","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637"},{"n":2,"title":"Drugs@FDA: Wegovy injection, application 215256","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256"},{"n":3,"title":"Drugs@FDA: Rybelsus and Ozempic tablets, application 213051","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051"},{"n":5,"title":"DailyMed: Wegovy injection and tablets prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"n":6,"title":"DailyMed: Rybelsus and Ozempic tablets prescribing information, revised January 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98"},{"n":10,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"section_is_it_legal":[{"n":1,"title":"Drugs@FDA: Ozempic injection, application 209637","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637"},{"n":2,"title":"Drugs@FDA: Wegovy injection, application 215256","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256"},{"n":3,"title":"Drugs@FDA: Rybelsus and Ozempic tablets, application 213051","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051"},{"n":4,"title":"DailyMed: Ozempic injection prescribing information, revised May 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79"},{"n":10,"title":"FDA: concerns with unapproved GLP-1 drugs used for weight loss, updated 1 October 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"},{"n":5,"title":"DailyMed: Wegovy injection and tablets prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"n":12,"title":"FDA: dosing errors with compounded semaglutide injections, 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"},{"n":7,"title":"FDA drug shortages: semaglutide injection, resolved","url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=r"},{"n":8,"title":"FDA order: the semaglutide injection shortage is resolved, 21 February 2025","url":"https://www.fda.gov/media/185526/download"},{"n":9,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":16,"title":"McDermott Will & Schulte: what the end of the semaglutide shortage means","url":"https://www.mcdermottlaw.com/insights/semaglutide-shortage-resolved/"},{"n":17,"title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs","url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs"},{"n":14,"title":"FDA: proposal to exclude semaglutide from the 503B bulks list, 30 April 2026","url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"},{"n":15,"title":"FDA warning letter to an online seller of research-use peptides, 24 August 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide+OR+Ozempic+OR+Wegovy+OR+Rybelsus&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/33567185/","https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637","https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded"],"verified_at":"2026-10-25T17:34:40.564Z","published_at":"2026-10-25T17:34:47.737Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-25T00:07:26.723Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}